Plenary Session Vinay Prasad, MD MPH

Today we interview Dr. Josee-Lyne Ethier of Queen's University in Kingston, Ontario, Canada on her new paper "Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer", out now in JAMA Oncology. We talk about the real-world survival outcomes for pertuzumab and T-DM1, comparing these outcomes to the results of pivotal clinical trials CLEOPATRA and EMILIA.

Practice Patterns and Outcomes: doi.org/10.1001/jamaoncol.2021.2140

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Today's episode is a compilation of a few short monologues. We provide an oncologist's evidence-based medicine perspective on four papers: CheckMate 274, adjuvant nivolumab in urothelial cancer; PARADIGM-HF/Entresto; the POLO trial, olaparib in pancreas cancer; and the paper "An algorithmic approach to reducing unexplained pain disparities in underserved populations".

CheckMate 274: doi.org/10.1056/NEJMoa2034442
PARADIGM-HF: doi.org/10.1056/nejmoa1409077
POLO: doi.org/10.1056/NEJMoa1903387
Knee pain: doi.org/10.1038/s41591-020-01192-7

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Today we sit down (in person!) with Dr. Jeff Bien of Stanford University to break down all the details -- from the methods to the statistical analysis to the conclusions -- of the CheckMate 649 trial, which pitted first-line nivolumab plus chemotherapy against chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma.

CheckMate 649: doi.org/10.1016/S0140-6736(21)00797-2

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Today we have two short monologues for you on recent papers. The first, by popular request, is the problems with the VISION trial, which treated metastatic castration-resistant prostate cancer with lutetium-177–PSMA-617 (Lu-177–PSMA-617) radioligand therapy and standard of care. The second is on the paper recently published in Science titled "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients".

Fecal transplant: doi.org/10.1126/science.abb5920

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

In today's quick episode, we talk about our new paper out now in JAMA Network Open titled "The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval"

ODAC Votes: doi.org/10.1001/jamaoncol.2021.3046

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

We have a reverse episode for you today! Emma Greenstreet, a second-year medical student at UCSF, interviews our usual host, Dr. Vinay Prasad on why and how he chose hematology/oncology as a specialty, engaging with criticism, mentorship, medical student rotations, choosing a research project, and urging doctors in academia to aim higher.

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew